Weei-Chin Lin, MD, PhD

Novel approaches to target MYC in ovarian cancer Many ovarian cancers express the cancer-causing MYC protein at unusually high levels. The activation of MYC is a hallmark of cancer initiation, progression, and resistance to therapy. Unfortunately, MYC is one of the most difficult proteins to target therapeutically. Development of an effective therapy against MYC activity […]

David George Huntsman, MD

Combining MEK inhibition with oncolytic viral therapy as a novel treatment for low grade serous ovarian carcinoma Low grade serous ovarian cancer (LGSC) is a rare form of ovarian cancer accounting for about 5% of ovarian cancer cases. While LGSC grows relatively slowly, it is stubbornly resistant to almost all therapeutics. As a result, outcomes […]

Viola Heinzelmann-Schwarz, MD

Multimodal single-cell surfaceome and transcriptome profiling of longitudinal high-grade ovarian cancer ascites samples Despite advances in the initial treatment of high-grade serous ovarian cancer (HGSOC), recurrence of the disease is very common and effective treatment of recurrent HGSOC remains a major challenge. In order for a tumor to gain resistance to chemotherapy and progress into […]

Naoko Sasamoto, MD

Using genetic predictors of CA125 to improve personalized ovarian cancer screening Most ovarian cancer cases are currently diagnosed at late stage when less than half of the women will live five years after their diagnosis. In contrast, ovarian cancer cases diagnosed at an early stage have more than 90% living after five years from diagnosis. […]

Jeremy Chien, PhD

Development of RAD51 degraders for ovarian cancer treatment PARP inhibitor drugs have had a major impact on the clinical treatment of ovarian cancer in recent years, but they do not work in all patients. Many tumors have genetic mutations that make the tumor unable to repair damage to its DNA. PARP inhibitors exploit this fact […]

Stefan Gysler, MD, MHS

Nerves as novel actors in the tumor microenvironment: the role of exosomes in ovarian cancer tumor innervation Although advances in surgery and chemotherapy for ovarian cancer have improved survival, most women with ovarian cancer will experience recurrence of their disease. Unfortunately, recurrent ovarian cancers respond poorly to chemotherapy and are incurable, highlighting the need for […]

Tao Wu, PhD

Tao Wu, PhDBaylor College of Medicine2020 Scientific Scholar Award Targeting Epigenetic Landscape Reprogramming to Combat Drug-resistance in Ovarian Cancer Despite major improvements in therapeutic approaches to ovarian cancer, the ability of tumors to develop resistance to anti-cancer drugs remains the major challenge in achieving longer-lasting remission. One of the ways drug resistance is thought to […]

T. Rinda Soong, MD, PhD

T. Rinda Soong, MD, PhDUniversity of Pittsburgh2020 Scientific Scholar Award Early Serous Tubal Proliferations as Alternate Precursors of High-Grade Serous Carcinoma Identifying the origins of high grade serous ovarian cancer can help us understand how to prevent this disease or detect it at earlier, more treatable stages. Precancerous changes in fallopian tube tissue known as […]

Matjaz Barboric, PhD

Matjaz Barboric, PhDUniversity of Helsinki 2020 James A. Harting Pilot Study Award Targeting transcriptional kinases for novel ovarian cancer therapies Ovarian cancer is the deadliest gynecological cancer. Identifying druggable Achilles’ heels of ovarian cancer can lead to new treatments. In order to do this, Dr. Barboric will target critical enzymes called cyclin-dependent kinases (tCDKs) which […]

Keith Knutson, PhD

Keith Knutson, PhDMayo Clinic Jacksonville2020 Cookie Laughlin Pilot Study Award Combination Th17-inducing vaccination and immune checkpoint blockade for ovarian cancer treatment Several types of immunotherapies that use the person’s own immune system to attack foreign “cancer” cells while leaving normal cells alone are being tested in ovarian cancer. Using immunotherapy to activate an immune pathway […]